Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Table 1 Baseline clinical characteristics of the study cohort

Characteristics	No. of patients (%)
Age
Years	58
Range	47-71
Gender
Male	28 (77.78)
Female	8 (22.22)
Number of metastasis sites
2	25 (69.44)
3	11 (30.56)
Metastatic site
Lymph node	21 (58.33)
Peritoneum	14 (38.89)
Liver	12 (33.33)
Lung	9 (25.00)
Others	10 (27.78)
Primary tumor site
Gastric	31 (86.11)
GEJ	5 (13.89)
ECOG score
0-1	30 (83.33)
2	6 (16.67)
Tumor grade
Well, differentiated	2 (5.56)
Moderately diff erentiated	9 (25.00)
Poorly differentiated	20 (55.56)
Unknown or missing	5 (13.89)
Histological subtype (Lauren classification)
Intestinal	16 (44.44)
Diffuse	10 (27.78)
Mixed	2 (5.56)
Unknown or not available	8 (22.22)
Previous treatment
Triplet: Platinum and fl uoropyrimidine with anthracycline	8 (22.22)
Doublet: Platinum and fl uoropyrimidine	27 (75.00)
HER2, EGFR, or other	1 (2.78)
Treatment line
1	26 (72.22)
2	10 (27.78)

GEJ: Gastroesophageal Junction Adenocarcinoma; HER2: Human epidermal growth factor receptor 2; EGFR: Endothelial growth factor receptor; ECOG: Eastern Cooperative Oncology Group.